Literature DB >> 24550137

MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.

Yi Yang1, Lei Liu, Ying Zhang, Hongyu Guan, Jueheng Wu, Xun Zhu, Jie Yuan, Mengfeng Li.   

Abstract

A microRNA usually has the ability to coordinately repress multiple target genes and therefore are associated with many pathological conditions such as human cancer. Our understanding of the biological roles of microRNAs in lung cancer, however, remains incomplete. In this study, we identified miR-503 as a tumor-suppressive microRNA in human non-small cell lung carcinoma (NSCLC), whose expression level correlates inversely with overall survival in NSCLC patients. Ectopic expression of miR-503 suppressed tumor cell proliferation and metastasis-related traits in vitro as well as in vivo, supporting a anti-cancer role of the microRNA in NSCLC progression. Mechanistic study revealed that oncogenic PI3K p85 and IKK-β were direct targets of miR-503. Overexpression of either PI3K p85 or IKK-β partially restored the malignant properties of NSCLC cells in the presence of miR-503. Taken together, our data demonstrate miR-503 inhibits the malignant phenotype of NSCLC by targeting PI3K p85 and IKK-β and might play a suppressive role in the pathogenesis of NSCLC, thus providing new insights in developing novel diagnostic and therapeutic approaches.
© 2014 UICC.

Entities:  

Keywords:  IKK-β; PI3K p85; lung cancer; miR-503

Mesh:

Substances:

Year:  2014        PMID: 24550137     DOI: 10.1002/ijc.28799

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

2.  MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression.

Authors:  Jianting Long; Caiwen Ou; Haoming Xia; Yifan Zhu; Dayue Liu
Journal:  Tumour Biol       Date:  2015-06-06

3.  Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells.

Authors:  Shuzheng Song; Guoqing Pei; Yaqiong Du; Jugang Wu; Xiaochun Ni; Shoulian Wang; Bojian Jiang; Meng Luo; Jiwei Yu
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

4.  MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1.

Authors:  Yun Liu; Xu Hu; Daokui Xia; Songlin Zhang
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

5.  Smad4 induces cell death in HO-8910 and SKOV3 ovarian carcinoma cell lines via PI3K-mTOR involvement.

Authors:  Yushuang Yao; Zhe Zhang; Fanmao Kong; Zhuqing Mao; Zhaoyuan Niu; Chuan Li; Aiping Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-10

6.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

Review 7.  Membrane microparticles: shedding new light into cancer cell communication.

Authors:  Paloma Silva de Souza; Roberta Soares Faccion; Paula Sabbo Bernardo; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-19       Impact factor: 4.553

8.  microRNA-503 suppresses the migration, proliferation and colony formation of prostate cancer cells by targeting tumor protein D52 like 2.

Authors:  Yuhua Chi; Feng Ding; Wenjie Zhang; Lifa Du
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

9.  Increased expression of microRNA-503 and reduced expression of kangai-1 in B-cell non-Hodgkin's lymphoma.

Authors:  Jingjing Wu; Aimin Li; Pengyu Zhang; Zhenchang Sun; Lijuan Han; Feifei Nan; L I Geng
Journal:  Exp Ther Med       Date:  2016-01-08       Impact factor: 2.447

10.  miR-503 inhibits cell proliferation and invasion in glioma by targeting L1CAM.

Authors:  Hao Liu; Zhi Song; Daguang Liao; Tianyi Zhang; Feng Liu; Wen Zheng; Kui Luo; Liang Yang
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.